IQDMA

IQDMA is an investigational small-molecule multi-kinase inhibitor designed to target the STAT3/5 signaling pathway, which is frequently hyperactive in Cutaneous T-cell lymphoma (CTCL). It acts by inhibiting several critical signaling hubs, most notably Anaplastic Lymphoma Kinase (ALK) and P21-Activated Kinase 2 (PAK2). PAK2 serves as a nuclear transporter for phosphorylated STAT5; thus, IQDMA-mediated inhibition of PAK2 results in a compartmental shift of pY-STAT5 from the nucleus to the cytoplasm, preventing its transcriptional activity. In preclinical murine models of mycosis fungoides, IQDMA has demonstrated significant anti-tumor activity, reducing tumor volume by over 90% and decreasing malignant T-cell proliferation and infiltration more effectively than conventional PUVA therapy. The drug is well-tolerated in animal studies, showing no significant systemic toxicity to major organs.